AVXL vs. LYEL, APLS, OGN, HCM, IBRX, AMRX, XENE, MIRM, ARWR, and AAPG
Should you be buying Anavex Life Sciences stock or one of its competitors? The main competitors of Anavex Life Sciences include Lyell Immunopharma (LYEL), Apellis Pharmaceuticals (APLS), Organon & Co. (OGN), HUTCHMED (HCM), ImmunityBio (IBRX), Amneal Pharmaceuticals (AMRX), Xenon Pharmaceuticals (XENE), Mirum Pharmaceuticals (MIRM), Arrowhead Pharmaceuticals (ARWR), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry.
Anavex Life Sciences vs.
Lyell Immunopharma (NASDAQ:LYEL) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership, dividends and community ranking.
Anavex Life Sciences has lower revenue, but higher earnings than Lyell Immunopharma. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Lyell Immunopharma had 3 more articles in the media than Anavex Life Sciences. MarketBeat recorded 7 mentions for Lyell Immunopharma and 4 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 1.53 beat Lyell Immunopharma's score of 0.44 indicating that Anavex Life Sciences is being referred to more favorably in the news media.
Anavex Life Sciences has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -323,792.09%. Lyell Immunopharma's return on equity of -34.64% beat Anavex Life Sciences' return on equity.
Lyell Immunopharma presently has a consensus price target of $20.00, suggesting a potential upside of 85.19%. Anavex Life Sciences has a consensus price target of $44.00, suggesting a potential upside of 441.87%. Given Anavex Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Anavex Life Sciences is more favorable than Lyell Immunopharma.
Anavex Life Sciences received 428 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 74.92% of users gave Anavex Life Sciences an outperform vote while only 43.75% of users gave Lyell Immunopharma an outperform vote.
66.1% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 31.5% of Anavex Life Sciences shares are owned by institutional investors. 25.1% of Lyell Immunopharma shares are owned by insiders. Comparatively, 11.4% of Anavex Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Lyell Immunopharma has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.
Summary
Anavex Life Sciences beats Lyell Immunopharma on 11 of the 18 factors compared between the two stocks.
Get Anavex Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anavex Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:AVXL) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy AVXL Stock Free AVXL Stock Alerts